Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.
Who will be affected?
Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM.
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM.
Nourallah A, Alshehri A, Alhejazi A, Usman B, ElGohary G, Malhan H, Motabi I, Al Farsi K, Al Shuaibi M, Siddiqui M, Ghonema RG, Taha R, Abouzeid T, Ahmed W, Diab M, Alhuraiji A, Rabea M, Chouikrat Z
Real-World Registry on the Pharmacotherapy of Multiple Myeloma and Associated Renal and Pulmonary Impairments in the Greater Gulf Region: Protocol for a Retrospective Real-World Data Study
REPAIR Multiple Myeloma, Real-World Registry on the Pharmacotherapy of Multiple Myeloma and Associated Renal and Pulmonary Impairments in the Greater Gulf Region: Protocol for A Retrospective Real-World Data
Abdelnaser Nourallah;
Abdulrahman Alshehri;
Ayman Alhejazi;
Binyam Usman;
Ghada ElGohary;
Hafiz Malhan;
Ibraheem Motabi;
Khalil Al Farsi;
Mohammed Al Shuaibi;
Mustaqeem Siddiqui;
Rasha Galal Ghonema;
Ruba Taha;
Tarek Abouzeid;
Wesam Ahmed;
Mohanad Diab;
Ahmad Alhuraiji;
Magdy Rabea;
Zahir Chouikrat
ABSTRACT
Background:
Multiple myeloma is the second most common cancer among hematological malignancies. Patients with active disease may experience several comorbidities, including renal insufficiency and asthma which may lead to treatment failure. Treatment of relapsed/refractory MM has been associated with multiple factors causing decline in progression-free survival as well as overall survival with subsequent lines of therapy. data about characteristics of this group of patients among Great Gulf region is lacking.
Objective:
Our primary objective is the detection of RRMM patients’ characteristic and treatment landscape in the Greater Gulf region.
Methods:
This regional, retrospective study collecting real-world and epidemiological data will be conducted in patients with multiple myeloma in countries of the GCC region. Medical records will be used to obtain required data. Between 150 to 170 patients’ records are planned to be retrospectively reviewed over a period of 6 months without any cross sectional nor prospective intervention. Cases will be collected from Saudi Arabia, United Arab Emirates, Kuwait, Oman and Qatar.
Results:
Descriptive as well as analytical statistics were obtained for this research. Calculated sample size allowed the estimation of the percentages of RRMM with an acceptable precision while complying with the challenges in the light of data scarcity.
Conclusions:
Although multiple myeloma is a predominant hematological disease, scarce data regarding its prevalence among published research for Great Gulf region is available. Consequently, the RRMM associated prognostic factors among Great Gulf patients are not revealed. Therefore, our study data will expand the vision regarding the incidence of MM as well as the associated factors that could lead to RRMM among Great Gulf citizens.
Citation
Please cite as:
Nourallah A, Alshehri A, Alhejazi A, Usman B, ElGohary G, Malhan H, Motabi I, Al Farsi K, Al Shuaibi M, Siddiqui M, Ghonema RG, Taha R, Abouzeid T, Ahmed W, Diab M, Alhuraiji A, Rabea M, Chouikrat Z
Real-World Registry on the Pharmacotherapy of Multiple Myeloma and Associated Renal and Pulmonary Impairments in the Greater Gulf Region: Protocol for a Retrospective Real-World Data Study